Grafting genetically-modified Schwann cells into a clinically-relevant SCI model
将转基因雪旺细胞移植到临床相关 SCI 模型中
基本信息
- 批准号:8470066
- 负责人:
- 金额:$ 3.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-04 至 2014-02-03
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectBrainCell SurvivalCell TransplantationCellsChestChronicCicatrixClinicalDiagnosisDiseaseExhibitsFoundationsGDNF geneGoalsGrowthIn VitroIndividualInjuryIschemiaLifeLinkLong-Term EffectsMediatingModelingMolecularMotorNatural regenerationNervous system structureNeuritesNeuronsParalysedPathway interactionsPropertyProteinsRecoveryRecovery of FunctionRegulationResearchSchwann CellsSecondary toSignal TransductionSiteSpinalSpinal Cord LesionsSpinal cord injuryStagingTimeTissuesTransplantationaxon regenerationcancer therapycellular engineeringclinically relevantdesigndisabilityeffective therapyexperiencegenetically modified cellsglial cell-line derived neurotrophic factorimproved functioningin vivoinjuredinsightmTOR proteinmigrationmyelinationneuroprotectionneurotrophic factornoveloverexpressionregenerativerelating to nervous systemrepairedtreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Grafting genetically-modified Schwann cells into a clinically-relevant model of SCI Spinal cord injury (SCI) is devastating, causing sensorimotor deficiencies, and possibly, complete paralysis. Unfortunately, there is no effective treatment, with hundreds of thousands living with the disorder and thousands more diagnosed each year. Overcoming primary damage, in addition to secondary tissue injury and glial scar formation, is critical for promoting axonal regeneration and functional recovery following SCI. Cell transplantation is a promising potential treatment for SCI. Schwann cells (SCs) are the most widely studied and these cells exhibit many benefits following SCI, such as promoting axonal regeneration and enhancing myelination. Though these functions are certainly advancements in SCI treatment, the full potential of SC transplantation has yet to be uncovered. Contusive injuries are one of the most commonly diagnosed forms of SCI, however much research has utilized hemi- or transection models, which are of less clinical value. Using SCs genetically modified to overexpress neurotrophic factors is promising as a potential treatment following SCI. We have recently shown that transplanting SCs engineered to overexpress glial cell line-derived neurotrophic factor (SC-GDNF) enhances neuroprotection and repair following SCI, and promotes astrocytic migration into the graft site, reducing inhibitory glial scar components in a hemisection SCI model. Also, co- administering SCs with GDNF following contusive SCI promotes significant neuroprotection and regeneration compared to SC transplantation alone. However, it is still not known what the short and long-term benefits of SC-GDNF transplantation are in contusive spinal cord injury. Also, the mechanism by which GDNF mediates structural protection and repair, or, very importantly, recovery of function, remains unknown. Activating mTOR, a pro-survival protein in the PI3K-Akt pathway may be one potential way GDNF exerts such effects. In addition, the long-term effects of GDNF expression by transplanted SCs on host tissue and function is unclear. To fully optimize this therapy for potential clinical use, it is essential to characterize the GDNF effect on neuroprotection, functional recovery and axonal regeneration in sub-chronic and chronic stages following contusive SCI, as well as its mechanism in enhancing neural regrowth following injury . In line with these goals, we hypothesize that transplanting SC engineered to overexpress GDNF into a thoracic contusive spinal cord lesion will 1) enhance neuroprotection, axonal sparing/regeneration, and functional recovery within a sub- chronic time course 2) promote and enhance such benefits into long-term chronic stages following SCI 3) enhance neurite outgrowth via activation of mTOR as a novel mechanism of its action.
描述(由申请人提供):将基因修饰的雪旺细胞移植到临床相关的SCI模型中脊髓损伤(SCI)是毁灭性的,导致感觉运动缺陷,并可能导致完全瘫痪。不幸的是,没有有效的治疗方法,每年有数十万人患有这种疾病,还有数千人被诊断出患有这种疾病。除了继发性组织损伤和胶质瘢痕形成之外,克服原发性损伤对于促进SCI后轴突再生和功能恢复至关重要。细胞移植是一种很有前途的脊髓损伤治疗方法。雪旺细胞(SC)是研究最广泛的,这些细胞在SCI后表现出许多益处,例如促进轴突再生和增强髓鞘形成。虽然这些功能在SCI治疗中肯定是进步的,但SC移植的全部潜力尚未被发现。挫伤是SCI最常见的诊断形式之一,然而,许多研究使用了半或横断模型,这些模型的临床价值较低。使用遗传修饰过表达神经营养因子的SC作为SCI后的潜在治疗是有希望的。我们最近的研究表明,移植过表达胶质细胞源性神经营养因子(SC-GDNF)的SC增强了SCI后的神经保护和修复,并促进星形胶质细胞迁移到移植部位,减少半切SCI模型中抑制性胶质瘢痕成分。此外,与单独的SC移植相比,在挫伤性SCI后共同施用SC与GDNF促进了显著的神经保护和再生。然而,目前尚不清楚SC-GDNF移植在挫伤性脊髓损伤中的短期和长期益处。此外,GDNF介导结构保护和修复的机制,或者非常重要的是,功能恢复的机制仍然未知。激活mTOR,PI 3 K-Akt通路中的促存活蛋白可能是GDNF发挥这种作用的一种潜在方式。此外,移植的干细胞表达GDNF对宿主组织和功能的长期影响尚不清楚。为了充分优化这种治疗方法的潜在临床应用,有必要表征GDNF在挫伤性SCI后亚慢性和慢性阶段的神经保护、功能恢复和轴突再生的作用,以及其在损伤后促进神经再生的机制。与这些目标一致,我们假设将工程化以过表达GDNF的SC移植到胸挫伤性脊髓损伤中将1)在亚慢性时程内增强神经保护、轴突保留/再生和功能恢复,2)促进和增强SCI后长期慢性阶段的这种益处,3)通过激活mTOR作为其作用的新机制来增强神经突生长。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chandler Walker其他文献
Chandler Walker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chandler Walker', 18)}}的其他基金
Exercise and NT-3-mediated lumbar motoneuron plasticity and recovery after SCI
SCI 后运动和 NT-3 介导的腰椎运动神经元可塑性和恢复
- 批准号:
10548164 - 财政年份:2020
- 资助金额:
$ 3.09万 - 项目类别:
Exercise and NT-3-mediated lumbar motoneuron plasticity and recovery after SCI
SCI 后运动和 NT-3 介导的腰椎运动神经元可塑性和恢复
- 批准号:
10329902 - 财政年份:2020
- 资助金额:
$ 3.09万 - 项目类别:
Adipose-derived stem cell-conditioned medium therapy in a mouse model of ALS
脂肪干细胞条件培养基治疗 ALS 小鼠模型
- 批准号:
9921214 - 财政年份:2019
- 资助金额:
$ 3.09万 - 项目类别:
Adipose-derived stem cell-conditioned medium therapy in a mouse model of ALS
脂肪干细胞条件培养基治疗 ALS 小鼠模型
- 批准号:
10359721 - 财政年份:2019
- 资助金额:
$ 3.09万 - 项目类别:
Adipose-derived stem cell-conditioned medium therapy in a mouse model of ALS
脂肪干细胞条件培养基治疗 ALS 小鼠模型
- 批准号:
10582528 - 财政年份:2019
- 资助金额:
$ 3.09万 - 项目类别:
Grafting genetically-modified Schwann cells into a clinically-relevant SCI model
将转基因雪旺细胞移植到临床相关 SCI 模型中
- 批准号:
8061914 - 财政年份:2011
- 资助金额:
$ 3.09万 - 项目类别:
Grafting genetically-modified Schwann cells into a clinically-relevant SCI model
将转基因雪旺细胞移植到临床相关 SCI 模型中
- 批准号:
8494101 - 财政年份:2011
- 资助金额:
$ 3.09万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 3.09万 - 项目类别:
Research Grant